Stock events for Codexis, Inc. (CDXS)
Over the past six months, Codexis stock has experienced significant volatility and decline, with the share price at $1.03 as of March 2, 2026, a 62.34% decrease from March 3, 2025. Key events include a Q3 2025 earnings report miss leading to a stock decline, a strategic shift and restructuring involving workforce reduction, a share price slump in February 2026, CEO Alison Moore outlining the company's strategic focus at the TD Cowen 46th Annual Health Care Conference, an agreement to manufacture siRNA, and upcoming Q4 2025 earnings.
Demand Seasonality affecting Codexis, Inc.’s stock price
The demand for Codexis's products and services appears to be influenced by customer manufacturing and clinical trial schedules, the adoption rate of its newer ECO Synthesis platform in the growing RNA therapeutics market, and the competitive landscape of its legacy biocatalysis business. The Q3 2025 revenue decrease was primarily attributed to variability in customers' manufacturing schedules and clinical trial progression. The company's strategic pivot to the ECO Synthesis platform and its focus on RNAi therapeutics manufacturing indicates a move towards a market driven by the long-term growth of advanced medicines. The legacy small-molecule biocatalysis business faces increased competition and commoditization for commonly used enzymes.
Overview of Codexis, Inc.’s business
Codexis, Inc. is a protein engineering company specializing in developing and commercializing novel enzymes and proteins. Founded in 2002 and headquartered in Redwood City, California, it operates within the Healthcare sector, focusing on Enzyme Engineering & Biocatalysis. Codexis leverages its CodeEvolver® technology platform to enhance enzymes used in various industries and has recently shifted its focus towards its ECO Synthesis™ platform for RNAi therapeutics manufacturing. Major products and technologies include the CodeEvolver® Technology Platform, ECO Synthesis™ Manufacturing Platform, biocatalysts and pharmaceutical intermediates, Codex Biocatalyst Panels and Kits, and an early-stage enzyme therapeutic product candidate for Phenylketonuria (PKU).
CDXS’s Geographic footprint
Codexis, Inc. is headquartered in Redwood City, California, U.S., with a key geographic presence extending across the Americas, Middle East and Africa, Europe, and Asia-Pacific (APAC).
CDXS Corporate Image Assessment
Codexis's brand reputation is closely tied to its strategic pivot and financial performance. The company is evolving its image to a "production solutions partner" in oligonucleotide manufacturing. Events affecting its reputation include the strategic shift to ECO Synthesis, partnerships and agreements with companies like Merck, financial performance challenges with revenue shortfalls, organizational restructuring with workforce reduction, and customer satisfaction with ECO Synthesis.
Ownership
Codexis, Inc. is primarily owned by institutional shareholders, who hold 71.60% of the stock, and Codexis insiders, owning 81.90%. Retail investors hold 0.00%. Major institutional owners include Standard Life Aberdeen plc, BlackRock, Inc., and Opaleye Management Inc. The largest individual shareholder is Vivo Ventures VII LLC, owning 16.16 million shares, representing 17.89% of the company.
